Cetera Advisor Networks
LRMR icon

Cetera Advisor Networks’s Larimar Therapeutics LRMR Stock Holding History

Cetera Advisor Networks’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-298
Closed -$4K – 2257
2020
Q2 		$4K Buy
+298
New +$3.47K ﹤0.01% 3057

Other funds holding LRMR

Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Logos Global Management
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return

Cetera Advisor Networks's LRMR Position: Q3 2020 in Review

Cetera Advisor Networks sold out of Larimar Therapeutics (LRMR) in Q3 2020, closing a stake of 298 shares — an estimated $4K sold.

Cetera Advisor Networks first reported a position in LRMR in Q2 2020 and held it in 1 quarter. The position peaked at $4K in Q2 2020. 38 funds tracked by Wall St. Rank hold LRMR as of Q3 2020.

  • Cetera Advisor Networks reported no remaining Larimar Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Cetera Advisor Networks sold 298 Larimar Therapeutics shares in Q3 2020, an estimated $4K.
  • Cetera Advisor Networks first reported a position in Larimar Therapeutics in Q2 2020 and held it in 1 quarter.
  • Cetera Advisor Networks's Larimar Therapeutics position peaked at $4K in Q2 2020.
  • 38 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2020.

Based on Cetera Advisor Networks's 13F filing for Q3 2020, filed 13 Nov 2020.